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Abstract
Neuraminidase inhibitors are the main pharmaceutical agents employed for treatments of influenza infections. The
neuraminidase structures typically exhibit a 150-cavity, an exposed pocket that is adjacent to the catalytic site. This site
offers promising additional contact points for improving potency of existing pharmaceuticals, as well as generating entirely
new candidate inhibitors. Several inhibitors based on known compounds and designed to interact with 150-cavity residues
have been reported. However, the dynamics of any of these inhibitors remains unstudied and their viability remains
unknown. This work reports the outcome of long-term, all-atom molecular dynamics simulations of four such inhibitors,
along with three standard inhibitors for comparison. Each is studied in complex with four representative neuraminidase
structures, which are also simulated in the absence of ligands for comparison, resulting in a total simulation time of 9.6ms.
Our results demonstrate that standard inhibitors characteristically reduce the mobility of these dynamic proteins, while the
150-binders do not, instead giving rise to many unique conformations. We further describe an improved RMSD-based
clustering technique that isolates these conformations – the structures of which are provided to facilitate future molecular
docking studies – and reveals their interdependence. We find that this approach confers many advantages over previously
described techniques, and the implications for rational drug design are discussed.
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Introduction
Influenza A and B viruses are responsible for the respiratory
disease commonly referred to as ‘the flu’, with infections ranging
from epidemics to pandemics and symptoms ranging from mild to
life-threatening. Inhibitors of viral neuraminidase (NA) have been
the mainstays of pharmaceutical treatment of influenza since their
initial introduction in 1999 [1]. Influenza NA is a tetrameric
exoglycohydrolase affixed to the viral membrane, which facilitates
viral proliferation by cleaving terminal sialic acid linkages on the
host cell to effect release of viral progeny. There are nine known
serotypes of NA (N1–N9) found in influenza A. These types are
further categorized into two groups based on phylogenetic
analysis; group-1: N1, N4, N5, N8, and group-2: N2, N3, N6,
N7, N9 [2]. All known NA possess highly conserved active site
residues and conformations, although crystallography has demon-
strated that group-1 NA generally exhibit a cavity adjacent to the
main sialic-acid-binding site that is not apparent in group-2 NA
crystal structures (CS). This cavity is known as the 150-cavity as its
accessibility is limited by a mobile loop composed of residues 147–
152, similarly known as the 150-loop. The 150-loop has been
crystallized in ‘open’ and ‘closed’ conformations [2,3], which
provide snapshots along a conformational itinerary.
The successful design of the two FDA-approved NA inhibitors,
zanamivir (Relenza) and oseltamivir (Tamiflu), can be attributed in
part to the conserved active site residues, the relative stability of
group-2 NA, and the lack of significant changes to the active site
upon ligand binding [1]. This is evidenced by the fact that the
rational structure-based design of these inhibitors was based
exclusively on the group-2 NA active site [1], predating discovery
of the 150-cavity in group-1 NA by some years [2]. Despite their
success, these inhibitors have limitations. Specifically, zanamivir
suffers from high polarity [1], oseltamivir is highly vulnerable to
inactivation due to viral mutation [4], and both exhibit mixed
clinical efficacy [5]. One recent strategy for simultaneously
improving the potency, lipophilicity, and capacity to resist
mutations of these compounds has been to attach groups, usually
hydrophobic, to a similar ring framework in order to form
additional points of contact within the 150-cavity [2]. Several such
compounds, known as 150-binders in this work, have been
synthesized [6–9] and many more have been proposed (see [10]
for a recent review). Some of these inhibitors have been shown by
X-ray crystallography to successfully enter the 150-cavity and
affect the orientation of the 150-loop [6], and others have
demonstrated powerful inhibitory activity in cellular assays [8,9]
and, recently, in vivo [8]. In contrast to zanamivir and oseltamivir,
150-binders are designed to interact primarily with the loop-open
NA conformations. This binding mode is promising in that the
group-1 loop-open NA conformation is thought to be lower in
energy than the loop-closed conformation [11], at least in group-
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1 NA, but it necessitates targeting portions of neuraminidase that
are far more dynamic than the active site, requiring a more
sophisticated understanding of NA-ligand dynamics. Crystallog-
raphy is likely to be less informative in this process as multiple
pieces of evidence have demonstrated the ambiguity of the static
structures of these dynamic systems. Specifically, adjusting
crystallization conditions can result in different structures for
identical systems [2], and it has been shown recently that even
strong binders can adopt distinct conformations in different CS
[12]. Further, MD simulations have revealed features previously
unobserved by crystallography, such as populated conformations
in which the 150-loop is open more widely than seen in any CS
[13], and that the 150-loop is predominantly open in 2009
pandemic N1 and occasionally open in N2 simulations [11],
despite their CS exhibiting only loop-closed conformations [2].
Moreover, as we demonstrate in this work, oseltamivir and
zanamivir generally reduce the mobility of various viral neur-
aminidases, while 150-binders typically exert the opposite effect,
giving rise to conformations that are not seen in simulations or CS
of neuraminidase in complex with standard binders. These factors
necessitate a more complex approach that examines the in-
terdependency of enzyme and ligand dynamics.
In this work, we seek to study such dynamics, utilizing long-term
MD simulations of a variety of NA, uncomplexed (apo) and in
complex with seven different inhibitors (holo), shown in Figure 1.
The ligands selected include the two commercial inhibitors,
zanamivir 1 and oseltamivir carboxylate 2, as well as a similar
inhibitor currently undergoing further study: the double-bond
isomer and guanidine derivative of oseltamivir 3 [7]. These
compounds, which we collectively refer to as ‘‘standard inhibi-
tors’’, serve both as controls and points of comparison to previous
computational and experimental studies. Additionally, four 150-
binders have been selected: two (4 and 5) featuring an alkene-
linked sidechain attached at C3 [6], and two (6 and 7) featuring
a triazole-linked sidechain attached at C4 [7]. Figure 2 shows the
CS conformations of these ligands, with 1, 2, 4, and 5 from the
PDB structures 2HTQ, 2HT8, 309J, and 309 K respectively, and
3, 6, and 7 from unpublished data. In all cases, these binding
modes of the ligands are similar. Inhibitors 4–7 have been studied
experimentally, and other proposed 150-binders have been studied
by molecular docking [14–16] and brief MD simulations [17,18].
However, there have been no reports on the complex ligand-
enzyme dynamics exhibited during long-term MD simulations of
150-binders.
Four neuraminidase CS that represent the diversity of known
NA structures were chosen for this work. These are an N2
structure (PDB code 2AEP and referred to as N2), the 2009
pandemic H1N1 structure (PDB code 3NSS and referred to as
N109), and the loop-closed and loop-open CS of N8 as crystallized
with 2 (PDB codes 2HT7 and 2HT8, and referred to as N8closed
and N8open, respectively.) N2 was selected as representative of
group-2 NA, which is known to be relatively static and exhibit
a high tendency towards loop-closed conformations [19]. N109 was
chosen as an atypical group-1 NA that is less dynamic and more
prone to a loop-closed orientation than is expected for this group
[3]. N8 was selected as a typical group-1 neuraminidase with CS
available for both the closed and open conformations. These
structures are useful as the N8closed structure highly resembles both
N2 and N109 in conformation, facilitating comparison between
their dynamics, while comparisons between N8open and N8closed
offer insights into the effects of loop-closed versus loop-open
conformations and the importance of starting-structures in MD
simulations [2].
Simulations of all four NA structures were conducted with all
seven ligands, as well as without any ligand, for three separately
equilibrated runs of 100 ns in length, resulting in a total simulation
time of 9.6 ms. The questions we set out to investigate in this study
are numerous. We sought to explore 1) the most populated
conformations of each ligand and each neuraminidase, as well as
their interdependency, 2) the active site residues’ stability or
flexibility in response to the various 150-binders, and the
implications for drug design, and 3) the commonalties among
and between the various ligands, specifically in regards to 3, which
shares features with each 1 and 2, i.e. the pentyloxy chain of 2 and
the guanidine moiety of 1.
We further demonstrate an improvement on the RMSD-based
clustering techniques that have proven valuable in numerous MD
studies, including multiple studies of influenza NA [11,16].
Standard clustering techniques were unsuitable for this study
due to the extensive simulation time, the flexibility of NA and
ligands observed, and the variety of NA and ligands included.
Standard clustering of each ligand-enzyme combination would
result in 28 separate groups of clusters, with each structure in each
group specific to that particular NA-ligand combination and
therefore not necessarily comparable to any other cluster structure.
Instead, we have extracted and concatenated the enzyme
coordinates from each run prior to clustering (see Materials and
Methods) in a process we refer to as ‘‘combined clustering’’. The
Figure 1. Compounds of interest.
doi:10.1371/journal.pone.0059873.g001
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result is just four separate groups of clusters that are common
within all simulations of a given enzyme, thereby facilitating
comparisons. The ligands are then separately clustered, separating
the dynamics of the ligands from those of the enzyme.
Owing to our primary interest in the important interactions, this
clustering was performed on the key residues of the active site as
shown in Figure 2, which are conserved across all NA employed in
this study. We excluded the 150-loop residues 147–150 as these
have been shown to be energetically unimportant for standard
inhibitors and fluctuate significantly [4]. We have additionally
employed a technique described in previous studies of measuring
the cavity-width in each simulation [4,11]. The width measure-
ments were correlated with the distances between ligand and
enzyme’s center of mass (COM) and their utility is compared to
RMSD-based clustering.
Results
Cavity-width and Loop Dynamics
Measurements of 150-cavity-widths, given in Table 1, generally
reflect conclusions from previous reports [4,11]. Specifically, N2 is
consistently in a closed-cavity state and shows little influence from
ligands. N109 is more dynamic, although it exhibits a closed-cavity
for 70% of all simulations and only slightly more in the apo
simulation. As expected, this is less flexible than N8; the
comparable N8closed remains closed for only 43% of the
simulations. The same N8 systems starting from an open position
consistently adopt more open conformations, spending an average
of only 8% of the simulation with a closed 150-cavity. This
indicates that the 20 ns of simulation time that was removed from
the start of each production run is insufficient to completely
overcome the bias of the loop starting position. The question of
starting-conformation bias is discussed in detail below.
Figure 3 displays the relationship between the cavity-width and
the ligand’s position by comparing the distance between the ligand
and the enzyme’s respective center of masses to the cavity-width
for that frame. The plot of compound 1 illustrates the potency and
stability of the standard binders, which are extremely static within
the enzyme’s active site and do not significantly alter the 150-
loop’s position relative to the apo enzyme runs. Compound 2 is
similar (Figure S1), while the 150-binders demonstrate a variety of
conformations within and outside the active-site, as reflected in
their COM distances.
Notably, the cavity-open conformation that is not seen in the
apo-N2 simulations is observed when N2 is complexed with 1, as
well with ligands 3 and 4. In all three cases, this takes place in one
of the three triplicate runs where the D147–H150 interaction is
lost, as previously reported [11], and only regained in the case of
1. The inconsistent appearance of an open 150-cavity for N2,
never occurring in more than one of the triplicate runs for a given
complex, is likely due to a lack of sampling. There is no clear
reason why ligands 5–7 would not similarly induce the 150-cavity
to open, or why apo-N2 is not observed with an open
conformation, as has been previously reported [11].
For the group-1 NA simulations, the results apparently contra-
dict the hypothesis that ligands facilitate loop-closure and 150-
binders inhibit loop-closure [6]. For example, ligands 6 and 7 in
Figure 2. Neuraminidase active site, N8closed and N8open. Active site of N8closed (left) with standard binders 1–3 and N8open (right) with 150-
binders 4–7. Compound 1 is shown in beige, 2 in yellow, 3 in purple, 4 in light blue, 5 in teal, 6 in grey, and 7 in brown. Key residues are labeled.
doi:10.1371/journal.pone.0059873.g002
Table 1. Loop-closed populations based on cavity-width.
Loop-Closed Population
Ligand N2 N109 N8closed N8open
1 93% 75% 53% 29%
2 100% 97% 21% 1%
3 71% 76% 38% 12%
4 77% 35% 17% 12%
5 100% 87% 36% 1%
6 100% 17% 67% 2%
7 100% 100% 70% 0%
Apo 100% 74% 42% 4%
Average 93% 70% 43% 8%
Std. Dev. 12% 29% 20% 10%
doi:10.1371/journal.pone.0059873.t001
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N8closed simulations are better able to encourage loop-open
conformations than even the standard binders. The simulations
of the remaining N8closed complexes are similar to the enzyme-
only state. N8open simulations are similar between all systems
(Table 1); only 1 is able to significantly induce loop closure.
Overall, there is no clear trend between ligand positions and
cavity-widths and inconsistent relationships between cavity-widths
of different NA and ligands. This is at least partly due to the
numerous and distinct loop conformations observed for the 150-
loop that nevertheless exhibit the same cavity-width, as shown in
Figure 4, especially in simulations with 150-binders. Determining
which qualify as loop-closed versus loop-open is accordingly
ambiguous, as no single distance measurement adequately
encapsulates the highly diverse variety of structures observed. It
Figure 3. Comparison of cavity-width and ligand distance from active site. Compound numbers are indicated within the frame, and
neuraminidases are as follows: N2 shown in black, N109 in blue, N8closed in green, and N8open in red. Compound 2 shows a profile that is extremely
similar to 1 and can be found in Supporting Information.
doi:10.1371/journal.pone.0059873.g003
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is therefore not possible to determine whether insufficient sampling
or measurement uncertainty is responsible for the lack of clear
trends based on cavity-widths. In contrast, the clustering analysis
described in the following section offers a clearer picture.
Active Site and Ligand Combined Clustering
Combined clustering greatly facilitates comparisons between
runs of the same enzyme with different ligands. For example,
with this method, cluster 1 (C1) for the apo-H3N2 run is
identical to C1 for all H3N2-ligand runs (though distinct from
C1 of the H1N1 runs). Clusters are numbered sequentially in
decreasing order of population over all simulations of that
particular enzyme. For all enzymes, the most populated cluster
C1 closely resembles the CS, with two minor observed
differences. E119 is somewhat twisted from its CS orientation
in all enzymes, and R118 is somewhat more recessed in N109
and N8open than in the corresponding CS. These features are
evident in Figure 5, which depicts the clusters of the apo-NA
simulations for all four enzymes along with the relevant CS for
comparison. This illustrates the conformation of each enzyme’s
C1 structure, its similarity to the original CS, as well as the
populated alternative conformations. Notably, apo-N8open does
not spend a significant amount of time in C1, mostly due to
R371’s frequent deviation from its CS conformation.
This approach necessitates clustering ligands separately, which
confers the added benefit of separating ligand motions from
enzyme motions and thereby facilitating evaluation of their
interdependency. By comparing cluster populations, for exam-
ple, it is possible to determine how a ligand’s various poses are
reflected in the conformation of the enzyme. In the text, the
results are summarized as follows: enzyme clusters are referred
to as C# while ligand clusters are referred to as L#. This
analysis results in plots of the conformation of a given enzyme
and the conformations of the complexed ligand over time. To
illustrate the utility of these results, an example of the resultant
plots for four N2 systems is shown in Figure 6 while the others
are provided as Text S1.
As can be seen from Figure 6, the stability of apo-N2 is
immediately obvious: the enzyme does not significantly deviate
from its CS-like conformation (C1). In complex with 2, N2
demonstrates similar rigidity while the ligand remains consistently
in its own CS-like pose (L1). 150-Binders 5 and 6, by contrast,
exhibit multiple conformations and also induce N2 into adopting
several alternative conformations. Details of these clusters are
given in the following sections, but several features bear noting as
they exemplify the versatility of this approach. For one, a particular
conformation (C3) is not seen in the apo-N2 simulation or
simulations in complex with standard ligands, but is common to
both N2–5 and N2–7 simulations. Further, there are several clear
correlations between enzyme and ligand conformations; for
example, N2–5 exhibits a ligand transition from L2 to L6 while
the enzyme transitions from C1 to C3/C5. Determining how
ligand conformations interact with enzyme conformations is thus
straightforward.
For the sake of brevity, in the following results sections only the
clustering results specific to ligands 1, 2, 3, 5, and 6 will be
discussed, which were chosen as representative of all seven ligands.
The results for the remaining two ligands are included in Text S2.
Only images necessary to highlight important insights are
presented below while images of all significant enzyme and ligand
clusters are provided as Text S3 and Text S4, respectively. In text,
all descriptions of NA and ligand motions are accompanied by the
relevant cluster label(s) and percentages in parentheses, which
indicate the populations of the specific cluster(s). While each
cluster is unique by definition, some motions lead to an excess of
clusters that do not differ significantly. For example, when a 150-
binder’s sidechain exits the active site and oscillates in solution,
several clusters may arise that do not differ in terms of important
conformations and interactions. Such groups of clusters are
typically described together within the same parentheses. Similar-
ly, when an important motion of an amino acid is common
between several clusters, such as R371 withdrawing, these clusters
are listed and their populations summed.
Figure 4. Independence of cavity-width and key residue conformations. Superposition of four MD snapshots of N8open-6 that exhibit
a cavity-width of 1.25 nm but differ significantly in conformations of key active site residues, shown as sticks.
doi:10.1371/journal.pone.0059873.g004
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Active Site Conformations in Apo-NA Simulations
The following descriptions correspond to Figure 5. Apo-N2 is
extremely static in simulation, as expected, remaining almost
entirely in its CS conformation (C1; 99%). By comparison, N109 is
far more mobile with significant populations in five clusters and
a low C1 population (C1; 34%). These additional conformations
stem primarily from changes in the two active site 150-loop
residues; D151 can recede (C3; 8%) or advance (C14; 9%); R152
can advance (C5, C14; 39%), fold down onto itself (C18; 4%) or
withdraw (C10; 12%). Additionally, Y406 fluctuates significantly
and can swing down toward E119 for a stable conformation (C10;
12%).
Apo-N8 is also quite dynamic, exhibiting nine populated
conformations in simulations starting from loop-closed and loop-
open conformations. In both cases, the residues that contribute to
distinct conformations are R118, D151, R152, R292, R371, and
Y406. For the N8closed simulations, the CS conformation is rarely
adopted (C1; 15%). Instead, R118 is often withdrawn (C4, C5, C9,
C17; 42%) but occasionally swings toward D151 (C2; 24%). R371
swings down away from the active site (C4, C6, C15; 14%). R292
frequently moves toward E276 and interacts there (C5, C6, C9,
C17; 34%). D151 occasionally recesses (C6, C9, C12, C17; 19%),
mutually moves toward R118 (C2; 24%), or extends toward the
active site (C15; 3%). R152 generally only fluctuates in place,
rarely extending toward the active site (C17; 3%). Y406 is
relatively constant, though occasionally extends up toward R292
(10%) or down to R118 (C12; 5%). In N8open simulations, the
most populated clusters for the native enzyme differ significantly
from the CS, as can be seen in Figure 5, with 0% population of
C1. R371 typically swings far from the active site (C12; 12%),
Figure 5. Superimposed active site clusters of all enzymes without ligands. Cluster conformations are depicted in yellow except for the C1
conformations of each enzyme, which are depicted in orange, and the CS conformations, which are depicted in purple. The transparency of each
conformation is inversely proportional to its population.
doi:10.1371/journal.pone.0059873.g005
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D151 and R152 together swing far away from the active site due
to backbone loop movements (C18, C23, C26; 15%), and E276
can swing toward R292 (C18, C21; 13%).
Conformations of NA Active Site and Complexed
Standard Binders 1 to 3
The N2-1, N2-2, and the N2–3 simulations exhibit similar NA
stability to the apo simulations; only C1 is highly populated for all
three. The ligands also do not stray significantly from the CS poses
with 100% populations in L1 for 1 and 2, and 97% for 3.
However, in one of the triplicate runs with 1, the ligand’s
guanidinium moiety encourages R156 to withdraw, causing E119
to follow and bend away from the active site. R118 simultaneously
withdraws somewhat as D151 bends toward the guanidinium as
well, and R152 swings toward the ligand’s amide (C3, C8; 13%),
as shown in Figure 7. Similar changes are evident in most
simulations with the guanidinium-containing ligands, 1 and 3.
With N109, the standard binders greatly reduce the mobility
seen in the apo simulation, yielding C1 populations increased from
34% to 96%, 100%, and 93% for 1, 2, and 3, respectively. The
conformation of 2 is essentially static, exhibiting a crystal-structure
pose for 94% of the simulation (L1) with a slight twist of its
pentyloxy chain for 4% of the simulation (L2). Similarly, 1
occupies its L1 conformation for 84% of the simulation, with the
glycerol chain twisting for 15% of the simulation (L2) toward R292
rather than R224. No other contacts are lost in this pose. R152
also rarely swings out of the active site (C17; 3%).
Figure 6. Cluster populations for selected N2 runs over time. Enzyme cluster populations are shown in blue, aligned to the left ordinate scale,
and ligand cluster populations are shown in red, aligned to the right ordinate scale.
doi:10.1371/journal.pone.0059873.g006
Figure 7. N2-1 alternate enzyme poses. Shown are the C1, C3, C8
of N2 with L1 of 3. The color scheme is identical to Figure 5.
doi:10.1371/journal.pone.0059873.g007
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In contrast, 3 seldom occupies its most CS-like conformation in
complex with N109 (L3; 8%). In its dominant cluster (L1; 70%),
the guanidinium group moves closer to the center of the active site,
greatly reducing the distances to electronegative Y406, E277, and
the alpha-carbonyl of W178. This pose, shown in Figure 8, does
not significantly alter the carboxylate-arginine interactions and the
enzyme typical remains in C1 (93%). However, the enzyme and
ligand frequently undergo a simultaneous transition where R371
withdraws (C15, C25, C28; 7%) and the ligand destabilizes
somewhat (L2, L5; 9%), as shown in Figure 8. This conformation
is similar to L1 and L3 though the carboxylate is now outside the
active site. This behavior is likely not seen in the N2–3 simulations
due to the greater rigidity of R371 and is the only example of
mobility of R371 in N109 simulations, suggesting that the ligand
exerts a significant effect on R371.
In simulations of N8 with the commercial ligands 1 and 2,
enzyme motions are again dramatically reduced in comparison to
the apo simulations. This results in increased C1 populations from
15% of apo-N8closed to 100% for both N8closed-1 and N8closed-2,
and from 0% in apo-N8open to 82% and 89% for N8open-1 and
N8open-2 C1 populations, respectively. In all cases, the ligand
rarely deviates from the CS-like pose L1, except for minor
rotations of the pentyloxy/glycerol groups. The N8open-1 enzyme
also occasionally occupies two similar clusters in which R118 and
D151 are somewhat extended toward the ligand and E276 has
withdrawn from R224 (C6, C24; 17%). The N8open-2 runs exhibit
one major enzyme motion, which is R118 swinging down toward
D151, with the latter moving toward it as well (C8, C36; 10%).
In contrast to 1 and 2, significant enzyme dynamics are again
observed in the N8closed-3 simulations (C1; 66%) where motions in
R118, R371, and R292 give rise to five populated enzyme clusters.
R118 frequently recedes to resemble a type-2 CS (C4, C14, C18,
21%), twice as often as seen in the apo-N8closed simulation, while
R371 swings away from the ligand (Figure 9). These swings also
occur without further changes to the active site (C6; 11%) and are
similar to the movements observed with N109-3 (Figure 8), further
supporting the destabilizing effects of 3 on R371. Simultaneously,
3 fluctuates within the active site and its carboxylate group
frequently drifts away from R371, encouraging R118 to recess and
allowing R371 to swing freely (L1, L3, L4, L6, L8, L9; 72%).
Without the strong R371 interactions, the ligand’s carboxylate can
then readily swing out of the active site (L2, L5, L7; 25%).
Nevertheless, the enzyme is significantly more CS-like than the
native enzyme overall, suggesting that 3 stabilizes C1 but to a lesser
extent than 1 and 2.
N8open-3 exhibits similar patterns as N8closed-3, with R371
frequently swung far back (C4; 28%) or R292 and E277 swung
toward E276 (C5; 28%). This is likely due to the position of 3
which exhibits poses that are similarly sunken as those observed in
N8closed simulations (L1, L2, L4, L5; 91%). There is significant
movement of the ligand’s carboxylate group, which occasionally
exits the active site (L2; 17%). Only during one triplicate does the
ligand adopt the CS-like pose and only infrequently (L3; 6%), but
during this time the enzyme rarely has R371 withdrawn (C4;
10%), demonstrating a correlation between these changes.
Conformations of NA Active Site and Complexed 150-
Binders 5 and 6
The 150-binders are far more dynamic than the standard
binders, especially in regards to their sidechains. Core interactions
such as carboxylate-arginine interactions are typically preserved,
however. As such, in complex with N2, 5 maintains a CS-like pose
for one of the triplicate runs but with its phenyl-sidechain
oscillating in (L7; 5%) and out (L2, L6; 29%) of the active site.
For the remaining two triplicates, only the ligand’s glycerol and
carboxylate moieties remain in the active site (L1, L3, L4, L5;
41.5%). Without significant correlation to the ligand pose, the
enzyme generally adopts either a CS-like pose (C1, 67%) or an
alternative conformation (C5; 25%) in which R152 is swung down
into the active site (Figure 10). This movement is facilitated by
contacts between the ligand’s hydroxyl and amide, and then
stabilized by electronegative carboxylate and carbonyl moieties
within the active site interior. Once formed, it then supports the
ejection of the ligand as is observed several times during the
trajectory. One additional enzyme pose, arising for 18% of the
time in which the ligand is CS-like is C3, where R118 and E119
move to interact with the ligand’s phenyl sidechain, and R152
swings toward the ligand hydroxyl.
Figure 8. N109-3 dominant pose and its destabilization. Shown
is C1, C15, C25 and C28 of N109 and L1 and L5 of 3. The color scheme is
identical to Figure 5.
doi:10.1371/journal.pone.0059873.g008
Figure 9. N8closed-3 ligand oscillations and R371 mobility.
Shown is C1, C4, C14 and C18 of N8closed and L1, L3, L4, L6, L8, and L9 of
3. The color scheme is identical to Figure 5.
doi:10.1371/journal.pone.0059873.g009
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In N2–6 runs, the ligand never adopts the expected pose though
remains within the active site for roughly one third of the
simulation time. The most CS-like poses (L1, L3, L4, L6; 60%)
differ in that the sidechain is angled directly under the D151 and
R152 residues, rather than adjacent to them. This binding mode is
similar to the sunken poses of ligand 3. While the ligand is
alternating between these flexible poses, it frequently loses its
carboxylate interactions (L3, L4, L6; 42%) while the enzyme
mainly resides in C1 (40%). Occasionally, D151 and R152 shift to
either side of the ligand’s triazole (C3; 19%), but more frequently,
these residues swing back (C6; 37%), as shown in Figure 11. This
ligand is thus able to force open the loop residues of the rigid N2
better than any other studied ligand, but is prone to alternative
binding poses. During the remaining 40% of the simulation, the
ligand is somewhat ejected from the confined enzyme active site;
only its carboxylate and sidechain remain within the active site
(L2, L5; 31%) and the enzyme is dominantly in C1 (98%).
During the N109-5 simulation, the enzyme is constantly in a C1
pose (98%). The ligand is almost always in a CS-like pose (L1;
66%) with its sidechain directed into the 150-cavity, suggesting
these conformations are not incompatible. The remaining
simulation time has the sidechain fluctuating in the solution
without an apparent impact on the enzyme.
In contrast, during simulations of N109-6 C1 is never occupied,
mostly due to variation in 150-loop residue D151 and nearby
amino acids (Figure 12). 6 adopts a CS-like pose for two of the
triplicate runs (L1, L2; 62%). In this pose, its electronegative
triazole group pushes back the electronegative D151 into the
solution, which thereafter interacts with the ligand’s sidechain
hydroxyl group (C3, C7, C9; 90%). This is similar to the
conformations of N2–6 with one exception; the recessed 150-loop
residues now adopt multiple distinct orientations. E119 and
occasionally R118 also interact with the ligand’s sidechain. The
ligand’s sidechain fluctuates outside of the active site during the
remaining triplicate although the key interactions remain intact
and the loop remains recessed (C3, C6, C9; 98%). Frequently,
Y406 moves forward to fill the gap (C6; 68%).
In complex with N8closed, 5 adopts multiple poses, all with the
key carboxylate interactions preserved. Only residues R118,
D151, and R152 exhibit different poses. While the ligand most
resembles the CS-like pose (L2, L6, L7; 32%), the enzyme is
typically in C1 (78%). However, the ligand’s sidechain frequently
clashes with D151, causing it to swing back, while R118 swings in
and interacts with the aromatic sidechain and R152 either remains
Figure 10. N2–5 facilitating R152 moving into the active site
center. Shown is C1 and C5 of N2 and L1, L3, and L4 of 5. The color
scheme is identical to Figure 5.
doi:10.1371/journal.pone.0059873.g010
Figure 11. N2–6 demonstrating a recessed D151–R152. Shown is
C1 and C6 of N2 and L1 of 6. The color scheme is identical to Figure 5.
doi:10.1371/journal.pone.0059873.g011
Figure 12. N109-6 shows a significant loop-opening effect.
Shown is C3, C7 and C9 of N109 and L1 and L2 of 6. C1 is included for
reference, though not occupied. The color scheme is identical to
Figure 5.
doi:10.1371/journal.pone.0059873.g012
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in its normal position (C3, 16%) or withdraws (C8, 10%). In
another populated pose, the glycerol chain contacts are lost and
the sidechain enters the solution (L1; 30%) while D151 is
periodically pushed away from the sidechain toward R152 (C7;
4%). In a third pose (L3, 23%), all contacts are maintained
although the side chain exits the active site and R118 again swings
in toward D151 as is seen with apo-N109 simulations (C2, C13;
70%). This interaction (Figure 13) prevents the ligand from re-
entering the 150-cavity, as is observable in the trajectory.
With N8closed, 6 often adopts a CS pose with its sidechain
frequently entering the 150-cavity (L1, L4, L7; 60%) while the
enzyme fluctuates between several conformations. Most interest-
ingly, the enzyme adopts a C1 conformation for 91% of the time
in which the ligand’s sidechain exits the active site, but only 44%
otherwise, demonstrating the sidechain’s impact. Instead, D151 is
often pushed far back (C3, C8; 41%) or turned toward R152 (C7;
13%), which occasionally swings in to interact with the ligand’s
hydroxyl group along with E119 (C8; 6%).
With N8open, 5 is considerably more dynamic, giving rise to 13
clusters with more than 1.0% occupation. The trajectory can be
divided into two groups; one in which the enzyme changes
conformation to accommodate the ligand, and the other in which
the reverse occurs. The former is constant for one of the triplicates
– the ligand adopts a CS-like pose (L1; 33%) during which time
the enzyme is predominantly in C3 and C28 (98%). In these poses,
D151 is swung toward R152 while R371, E276, and E277 are
withdrawn, demonstrating successful blocking of the loop by the
ligand. In the remaining two triplicate runs, the ligand is largely
outside of the active site (L2–L13; 94%) with only the carboxylate
interaction intact. The enzyme meanwhile adopts a CS-like pose
(C1, C6, C22; 94%) with minor movement in R118. Occasionally
the loop recedes somewhat (C5; 4%).
In simulation with N8open, 6 adopts a CS-like pose for the
beginning of all three triplicates (L1; 50%) while the enzyme’s 150-
loop is forced open (C2, C3, C13, C14, C19; 91%). Occasionally
R118 swings in toward the ligand’s triazole moiety (C14; 4%),
remaining as stable arrangement for one entire triplicate. In
another triplicate, the ligand exits into the solution while the loop
continues to oscillate, and in the remaining triplicate the loop
closes (C1; 8.3%) and thereby displaces the ligand’s sidechain (L5;
5%), shown in Figure 14. These runs demonstrate that 6 can be
stable within the active site, or with its sidechain directed into the
solvent, while the loop fluctuates or rests in a closed conformation.
Discussion and Conclusions
The above discussion detailed the motions and binding modes
observed throughout the simulations, and several key results from
the clustering analysis are summarized in Table 2. This table lists
the populations of the CS-like C1 populations, summed popula-
tions of every loop-closed conformation for each enzyme, the
summed population of ligand conformations in which the ligand
remains within the active site, as well as the latter’s impact on loop
closure. Specifically, the total populations of loop-closed con-
formations that occur while the cavity is fully occupied are given.
By comparing the propensity of an enzyme’s 150-loop to close in
the apo state, versus when in complex with a specific ligand, and
further when that ligand is fully within the active site, the ligand’s
influence on the loop can be better quantified. For example, in
complex with 4, N109 exhibits a reduced loop-closed population of
39% relative to 77% of the apo simulation. However, during the
30% of the simulations in which 4 is entirely within the active site,
the loop-closed population increases to 85%. This reveals that the
N109-4 complex is far more likely to exhibit a closed 150-loop
when the ligand is within the active site than when the ligand is
partially exited, contradicting the expected effects of these 150-
binders of forcing open the 150-loop by occupying the 150-cavity
[6]. Instead, it appears that it is the fluctuations of 4 that
encourage the 150-loop of N109 to open.
In the absence of any ligand, the enzymes vary significantly in
mobility. The C1 population of N2 is nearly 100%, dropping to
35% for N109, and further to 16% and 0% for N8closed and
N8open, respectively. These conformational changes are not purely
derived from loop mobility though; N109 adopts loop-closed
conformations for 77% of the simulations, indicating that the
Figure 13. 5 is blocked from reentering the active site of
N8closed. Shown is C2 and C13 of N8closed and L3 5. C1 is included for
reference. The color scheme is identical to Figure 5.
doi:10.1371/journal.pone.0059873.g013
Figure 14. Simultaneous 150-loop closure and ligand sidechain
ejection for N8open-6. Shown is C1 and C3 of N8open with L1 and L2
of 6. The color scheme is identical to Figure 5.
doi:10.1371/journal.pone.0059873.g014
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majority of its mobility is due to fluctuations in amino acids that
are not part of the 150-loop. Similarly, N8closed and N8open remain
loop-closed for 37% and 18% of the apo simulations, respectively,
suggesting that roughly half of their conformational flexibility is
due to loop movement. These closed-loop values are similar to
those determined by cavity-width monitoring, supporting the
validity of this measurement for apo systems. However, there is
little correlation between loop-closed conformation populations
and cavity-width for the simulations without complexed ligands.
Regarding ligand dynamics, the standard binders are almost
entirely stable within the active site, as demonstrated by the
average values for each ligand given in Table 2. 150-Binders, by
contrast, remain within the active site less often, yielding averages
from 38% for 4 to 61% for 6, likely due to their lower binding
affinities. In fact, the trend of these average active site populations
matches the known potency of these compounds:
1<2<3.6.7.5.4 [6,7]. In general, measuring cavity-occupa-
tion by inspection of cluster structures yields better results than
COM-distances, which are less able to discern ligand fluctuations
and reorientations.
In line with their stability, the conformations of standard
binders 1 and 2 are extremely static, as has been reported
previously. Only twists of the pentyloxy and glycerol chains are
observed. Ligand 3, despite its similar structure, potency, and
active site occupancy to 1 and 2, is notably more dynamic. It
averages 4.8 populated conformations – several more than 1 or 2 –
Table 2. Clustering results summary by neuramindase.
NA Ligand CS-like Pop. Loop Closed Population
a
Ligand in Active Site
Populationa Populated Conformations
a
Overall
While Ligand
is in Active
Siteb Enzyme Ligand
N2 Apo- 99% 99% – – 1 –
1 86% 100% 100% 100% 2 1
2 100% 100% 100% 100% 1 1
3 98% 98% 98% 100% 1 2
4 63% 93% – 0% 2 2
5 67% 98% 100% 33% 2 9
6 58% 77% 37% 35% 2 6
7 42% 42% 42% 100% 3 2
N109 Apo- 35% 77% – – 3 –
1 97% 99% 99% 100% 2 2
2 100% 100% 100% 100% 1 3
3 94% 98% 98% 96% 1 5
4 32% 39% 85% 30% 3 7
5 98% 98% 100% 67% 1 4
6 1% 1% 0% 69% 3 6
7 5% 8% 7% 52% 2 6
N8closed Apo- 16% 42% – – 4 –
1 100% 100% 100% 100% 1 1
2 100% 100% 100% 100% 1 2
3 66% 73% 74% 93% 3 8
4 91% 92% 91% 66% 2 7
5 56% 59% 77% 64% 4 6
6 59% 59% 48% 75% 3 10
7 60% 60% 49% 71% 2 6
N8open Apo- 0% 22% – – 5 –
1 83% 100% 100% 100% 2 2
2 90% 100% 100% 99% 2 2
3 41% 42% 42% 98% 2 5
4 51% 84% 85% 57% 4 5
5 47% 60% 7% 36% 3 9
6 8% 10% 2% 65% 4 9
7 0% 18% 0% 6% 3 11
aSee materials and methods for criteria.
bPercentage of simulation time that a loop-closed cluster is occupied while the ligand remains in the active site.
doi:10.1371/journal.pone.0059873.t002
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while stabilizing the closed-loop conformations less and inducing
an unexpected mobility of R371. It is surprising that, despite the
frequent loss of the energetically important carboxylate-R371
interactions [4], this inhibitor exhibits comparable potency to 1
and 2 [7]. This could be due to the viability of alternative poses for
3, which were observed in multiple simulations and are shown in
Figures 8 and 9. This flexibility may also be responsible for the
unreduced potency of 3 against oseltamivir-resistant influenza
strains with the H274Y mutation [7], which reportedly target the
pentyloxy group of 2 that is common to 3 [20]. Given that the
potency of 1 is similarly not reduced by the H274Y mutation [20],
it is possible that the common guanidinium moiety is a factor.
Unlike the standard binders, the 150-binders do not reduce the
mobility of the enzyme, exhibiting similar populated enzyme
conformations relative to apo simulations. However, 150-binders 4
and particularly 5 increase the population of the CS-like
conformations relative to the apo simulations, much like the
standard binders. 150-Binders 6 and 7, by contrast, do not
significantly alter the CS-like conformation populations but do
significantly increase the tendency of NA to adopt loop-open
conformations. This effect is significantly pronounced for com-
pound 6 when considering only the period in which the ligand is
fully within the active site, indicating that its relative instability
reduces its capacity to lock open the 150-loop. The six other
ligands, in contrast, did not demonstrate significantly different
behavior overall when only considering the periods in which they
remain entirely within the active site. Overall, compound 6 is most
representative of a successful 150-binder, exhibiting a relatively
high active site population (61%), an average decrease of loop-
closed populations of 37% relative to apo simulations, and
a greater reduction of loop-closed populations (20%) when fully
within the active site.
On the importance of starting conformations, as demonstrated
by comparing N8closed and N8open, it is clear that the position of
the 150-loop exerts a significant effect on the behavior of the NA
and the ligands. There is greater mobility observed for N8open,
which exhibits more significantly populated conformations and
decreased C1 and loop-closed populations than N8closed. These
effects are reduced in simulations of the standard binders, which
generally equilibrate quickly and exhibit greater stabilities. The
150-binders, in contrast, are more likely to exit the active site
during the N8open simulations – especially 7, which features
a sidechain that is relatively stable in solution (Text S2). Generally,
these results demonstrate that triplicate simulations of 100 ns are
insufficient for overcoming starting-conformation bias for all
simulations except those with standard binders. This is confirmed
by analyzing the clustering analysis results as 20 ns blocks (Text
S5), which suggests that cluster populations are generally stable
over the length of the simulation after removing the initial 20 ns.
This suggests that in order to overcome the bias of the beginning
orientation of the 150-loop, removing more than 20 ns – at least
100 ns – from the beginning of simulations prior to analysis would
be necessary. This would require simulations of much greater
length than 100 ns, at least for the mobile N8 systems, if both
loop-closed and loop-open structures are not employed. It is
unclear whether the more stable N109 and N2 simulations are
equally sensitive to starting loop-orientations, and therefore
whether prior analyses of the free energy of loop closure are
reasonable [21].
In comparison to cavity-width monitoring and COM measure-
ments, combined clustering offers clearer trends between ligand
positions, the 150-loop’s conformation, and NA fluctuations,
which we attribute to several factors. For one, the cavity-width
appears to require more sampling overall. This is evidenced by the
consistency of the results for the apo systems, which equilibrate
faster, in comparison to the holo systems, which lack clear trends.
Secondly, the variety of loop positions cannot be simplified to
a single distance measurement as argued above (Figure 3). Thirdly,
COM measurements are ambiguous, being unable to distinguish
between a variety of ligand positions that may share the same
COM, for example. Finally, combined clustering is far better able
to analyze shared conformations between diverse systems, which
allows for straightforward tabulation of CS-like populations, loop-
closed conformations, and enzyme mobility.
Another common measurement of mobility, root mean squared
fluctuation (RMSF), was also evaluated. However, in general,
these values offer less insight than the number of populated
conformations available from clustering. The average apo NA
adopts seven significantly populated conformations, dropping to
five when in complex with 150-binders, and two when in complex
with standard inhibitors. In contrast, RMSF values (Text S6) attest
to the stability of N2 and the mobility of N8, relative to N109, but
otherwise show few clear trends between the various complexes.
This is because RMSF values cannot distinguish between a residue
that generally only oscillates rapidly in place, such as Y406, from
a residue that adopts multiple conformations, such as D151.
Overall, this work highlights the extremely complex and
dynamic interactions of influenza neuraminidase with its
inhibitors. This is particularly true for the 150-binders studied,
which are more prone to exiting the active site and are more
dynamic than the standard binders. None of these ligands
demonstrated all of the desired characteristics of this class,
though compound 6 is nearest. In general, detailed analysis is
required to discern the impact of ligand mobility, which is
generally deleterious for the 150-binders but can be beneficial,
as for compound 3. Similarly, interesting phenomena occur
frequently that are entirely dynamic in nature, such as partially
exited ligands encouraging the NA to adopt unique poses that
in turn prevent the ligand from reentering the active site (ligand
5 in particular). Future design of 150-binders will require
significant consideration of such dynamics, which are readily
probed by MD simulations and clustering techniques. The
results of combined clustering in particular can be efficiently
analyzed to determine the interdependency of given conforma-
tional changes, such as the relation between loop-closed
populations and active site occupation. Cavity-width monitoring,
in contrast, appears well suited for apo systems but does not
give meaningful results for holo simulations. Additionally,
molecular docking approaches may better account for NA
dynamics by including a greater variety of NA conformations,
such as the cluster-centroid structures of this work (provided as
Structures S1).
One of the central challenges of improving the potency of
150-binders is that increased loop-open conformation popula-
tions are associated with ligands increasingly exiting the active
site, as evidenced by decreased active site populations for
compounds 4–7 in complex with N8open versus N8closed. This is
likely related to a decrease in binding affinity. Although our
results confirm the relative stability of the loop-open state for
the typical group-1 N8 systems, in the absence of binding
ligands, loop closure is certainly an energetically favorable
process in the presence of the strongest inhibitors, 1 and 2.
Therefore, the ideal 150-binders may similarly induce loop
closure by maintaining contacts with the 150-loop residues,
while also forming additional contacts within the 150-cavity.
Our results indicate that such conformations are possible.
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Materials and Methods
System Preparation
All systems were prepared in a standardized fashion to allow for
convenient automation via scripting. For each individual protein
and ligand, properly aligned, parameterized, and processed
structure files were first produced. These structure files were then
combined to produce all complexes, prior to simulation. All
protein structures (2AEP, 3NSS, 2HT7, 2HT8) were first validated
and repaired with MolProbity [22]. The ‘A’ chain of each was
extracted and uploaded to the PDB2PQR server [23], in which
histidine residues were protonated at pH 6.5 and verified
manually. Disulfide linkages were enforced with the proper
AMBER notation and the resultant files were input into tleap of
Amber 12.0 [24], automatically renumbered, then exported as
pdb files. All structures were then imported into PyMOL and
aligned [25]. Crystallographic water molecules from all CS that
did not clash with any of the ligand-enzyme complexes were
combined and added to each structure, along with the key calcium
ion if absent [26], and the structure was output. Each ligand was
constructed and subjected to at least one dozen optimization
calculations, at the Hartree-Fock level using the 6-31G* basis set,
from different conformations in Gaussian 09 [27]. RESP charges
[28] for each unique conformation were then derived using
multiple-orientations from single point calculations input to the
R.E.D. server [29]. Slight variations in atomic positions yielded
charges that varied significantly, and therefore the set of charges
that were most consistent among and between the ligands was
selected (Text S7). All ligands were then docked into 2HT7 using
AutoDock Vina [30]. As the top-scoring poses did not consistently
agree with crystallographic data, the poses for each ligand were
selected manually. For ligands 1, 2, 4, and 5, those that matched
most closely to the PDB structures 2HTQ, 2HT8, 309J, and
309 K, respectively, were selected. For ligands 3, 6, and 7, the
poses were similarly chosen by comparison to unpublished
crystallographic data for each ligand, yielding similar binding
modes to the other ligands in all cases. Each ligand’s pose was then
combined with the relevant atomic charges described above to
produce Tripos mol2 files. Complexes of all ligands and enzymes
were then produced via combination in tleap. All proteins were
then parameterized using Amber ff99SB, and all ligands were
parameterized with the General Amber Force Field (GAFF) [31]
with the corresponding RESP charges, using tleap and antecham-
ber. AMBER files were then exported.
Molecular Dynamics Simulations
MD simulations of all systems were conducted with the
GROMACS suite, version 4.5.4 [32], utilizing the Amber ff99SB
force field [33]. AMBER files for each complex were converted
into GROMACS formats using ACPYPE with the ‘‘gmx45’’
option [34]. Each system was placed in a dodecahedral box with
a minimal 12 A˚ distance between solute and box edge and
solvated with TIP3P water molecules. Salt ions were then
introduced to achieve a concentration of 0.15 M and neutralize
the overall charge. Each system was then treated to at least two
alternating rounds of 5000 steps of steepest descent and conjugate
gradient minimization. Following minimization, random velocities
were generated in the first step of equilibration to yield unique
triplicate runs of each system. Equilibration entailed first gradually
heating the system from 0 K to 300 K in 60 K increments with
a Berendsen thermostat during simulations of 40 ps duration.
Position restraints on solute molecules began at 1000 kJ mol–
1 nm–2 and were reduced by 200 kJ mol–1 nm–2 per incremen-
tal run. Pressure was then equilibrated during three steps. First,
with 200 kJ mol–1 nm–2 solute restraints, a Berendsen barostat
with a time constant of 2.0 ps and a reference pressure of 1.0 atm,
and a Berendsen thermostat with a time constant of 0.5 ps and
a reference temperature of 298 K. After 100 ps, position restraints
were removed for an additional 100 ps simulation. Finally, the
pressure and heat controls were changed to a Nose-Hoover [35]
thermostat and a Parrinello-Raham barostat [36], and the system
was equilibrated for a final 400 ps before beginning production
runs with the same configuration. Throughout, the LINCS
algorithm was used to constrain bonds involving hydrogen atoms
and the leapfrog integrator was employed with a 2 fs time step.
Short-range interactions were calculated with a cut-off of 1.0 nm
for columbic interactions and 1.3 nm for van der Waals
interactions. Long-range electrostatic interactions were calculated
with the particle mesh Ewald (PME) algorithm using a grid spacing
of 0.12 nm and an interpolation order of 4. Neighbor lists with
a 1.0 nm cutoff were updated every 5 steps.
Table 3. Averaged clustering results and standard deviations.
Apo 1 2 3 4 5 6 7
CS-like Population 38% 91% 97% 75% 59% 67% 32% 27%
Std. Dev. 42% 17% 8% 33% 25% 22% 31% 29%
Loop Closed Populationa Overall 60% 100% 100% 78% 77% 79% 37% 32%
Std. Dev. 31% 1% 0% 29% 32% 35% 33% 34%
While Ligand is in Active Siteb – 100% 100% 78% 88% 76% 20% 35%
Std. Dev. – 1% 0% 32% 36% 46% 18% 27%
Ligand in Active Site Populationa – 100% 100% 97% 38% 50% 61% 57%
Std. Dev. 0% 0% 4% 40% 50% 39% 45%
Populated Enzyme Conformations 3.0 1.4 1.2 1.8 2.8 2.6 2.9 2.8
Std. Dev. 0.6 0.7 0.6 0.8 1.6 1.2 1.4 1.1
Populated Ligand Conformations – 1.4 2.0 4.8 5.3 7.0 7.7 6.3
Std. Dev. 0.4 0.5 1.8 2.8 3.7 4.5 4.1
aSee materials and methods for criteria.
bPercentage of simulation time that a loop-closed cluster is occupied while the ligand remains in the active site.
doi:10.1371/journal.pone.0059873.t003
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Trajectory Analysis
RMSD plots of all heavy protein atoms (Text S8) and all heavy
active site atoms (Text S9) of all systems illustrated general
convergence after no longer than 20 ns of post-equilibration
simulation time. Accordingly, the first 20 ns of all trajectories were
discarded and the three triplicate runs were concatenated prior to
analysis, yielding 240 ns of fully equilibrated simulation time for
each of the 28 systems. All systems were aligned based on the
alpha carbons of the 100 NA residues with the lowest RMSF
values. Cavity-width was measured using the GROMACS suite as
the minimal distance between the alpha-carbon of residue 431 and
the sidechain carbons of residue 149 [4,11]. Centre of mass
distances between ligands and enzymes were measured from all
non-hydrogen ligand and enzyme atoms. Combined clustering
was performed by extracting the enzyme trajectories from all
systems, then renumbering residues and atoms to ensure that all
numberings of apo and holo systems of the same enzyme matched.
All trajectories of the same enzyme were then concatenated. A
38401 by 38401 RMSD matrix for the combined trajectories of
each was then calculated from a time step of 50 ps and based on
the sidechain heavy atoms of key, conserved active site residues:
R118, E119, D151, R152, W178, R224, E227, E276, E277,
R292, R371 and Y406. Clustering was then performed on each
combined enzyme trajectory using the Gromos algorithm [37] as
implemented in the GROMACS package with a RMSD cut-off of
0.12 nm. This cut-off was chosen as the optimal balance between
the number of clusters and their meaningfulness, after experi-
menting with values from 0.10 to 0.25 nm. Comparison of the
cluster centroids to the averaged cluster structures allowed
confirmed that the centroid structure was representative of all
relevant frames. Ligands were clustered separately by the same
method, although based on all heavy atoms and a RMSD cut-off
of 0.13 nm. Results for the enzymes were separated and sorted via
custom Python scripts and assembled along with the ligand clusters
in spreadsheets to facilitate interpretation. To assemble the
information in Table 2, NA clusters were deemed to be ‘‘loop-
open’’ if the 150-loop residues D151 and R152 met two criteria.
First, the RMSD difference between D151 and R152 of the cluster
in question and of the most CS-like cluster was greater than
0.450 A˚. Secondly, the distance between the terminal oxygen
atom of Y406 of the most CS-like cluster and the carboxylate
carbon of D151 of the cluster in question was greater than 8.50 A˚,
or the distance from the same oxygen to the arginine carbon of
R152 of the cluster in question was greater than 10.80 A˚.
Similarly, ligand poses were deemed to be within the active site if
the majority of their atoms were within the active site cavity,
regardless of conformation. However, if sidechains of the 150-
binders were directed into the solvent, the pose was deemed to not
be within the active site as the sidechain occupying the 150-cavity
is an essential requirement of 150-binders. Structures of the
clusters are provided as Structures S1. The average values in
Table 3 were generated by averaging all individual runs for each
ligand. For the values of loop-closure while the ligand is within the
active site, the average was proportionally weighted towards runs
in which the ligand occupies the active site for a longer period.
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